Navigation Links
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:9/25/2007

- Study Will Assess Drug's Benefit, Alone and With Lipitor(R), in Overweight or Obese Patients with High Cholesterol and Triglycerides -

HAYWARD, Calif., Sept. 25 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug's effect on dyslipidemia, insulin-resistance and obesity.

Preclinical and clinical testing of MBX-8025 indicates that the drug has the potential to improve a number of lipid parameters that are abnormal in different types of dyslipidemia, including high LDL (or "bad") cholesterol, high Apo B-100 (the atherogenic lipoprotein), low HDL (or "good") cholesterol and high triglycerides (fats). In addition, MBX-8025 has been shown to exhibit positive effects on insulin sensitization and body weight. The randomized, double-blind Phase 2 trial will assess the potential of the drug alone and in combination with Lipitor(R) (atorvastatin).

"Although high LDL levels are widely treated as a risk factor for heart disease, many patients are unable to reach increasingly low LDL targets on a statin alone. Additionally, existing drugs do a poor job of targeting the entire range of different lipid disorders that contribute to cardiac risk. We believe this trial will provide us crucial evidence in assessing the ability of MBX-8025 to lower Apo B-100, LDL and triglyceride levels, as well as raise HDL levels, improve insulin sensitivity and reduce body weight," said David B. Karpf, M.D., the chief medical officer of Metabolex. "In addition, we are testing the drug in conjunction with Lipitor, the best-selling lipid-lowering drug in the world, to determine whether combination therapy with a statin will be well tolerated and lead to even better results."

The study will
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- As kids transition from ... of cyberbullies, according to a recent study. ... through 8 found that verbal and physical bullying declines ... bullying intervention and prevention strategies must address all types ... boys and girls, the researchers said. The study was ...
(Date:9/19/2014)... Visiting Nurse Association (VNA) Health Group, ... hospice and palliative care and community-based care, was honored ... yesterday at the New York Stock Exchange. , Founded ... entrepreneur to care for immigrant families suffering from tuberculosis ... to meet the urgent healthcare needs of the communities ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lipitor lawsuits ... caused some patients to develop Type 2 diabetes continue ... underway in U.S. District Court, District of South Carolina, ... issued on September 12, 2014, discovery is underway and ... report noted that Pfizer, Inc., the manufacturer of Lipitor, ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Research predicts possible 6,800 new Ebola cases this month 2
... is one of the leading causes of blindness. The cause ... raised pressure within the eye, (the intraocular pressure), that can ... damage results in poor blood supply or weak end eye ... the optic nerve leading to the brain. Fluid enters and ...
... imaging test may identify patients with the gene mutation ... Doppler tissue imaging (DTI) as a more powerful way ... Hypertrophic cardiomyopathy (HCM) causes thickening of the left ventricle ... of sudden cardiac death in the young, affecting one ...
... recent study, the researchers confirmed that people who consume high ... lungs. And for the first time, the research showed that ... decline in lung function over time.// Just like an apple ... may help keep lung disease away, according this new research. ...
... makes detection more easier. A combined scanner detects more ... method. It is notoriously difficult to get an accurate ... is dense and so it's not always possible to ... at the University of Texas now say that combining ...
... to a recent study, a rare genetic condition has uncovered ... unusual childhood genetic disorder marked by bone marrow failure. If ... of a number of cancers, including brain, head and neck, ... and the Children's Hospital, Boston, have been studying a number ...
... Hormone replacement in patch form improves mood and libido ... difficulty reaching orgasm and painful intercourse. They assume it's ... no licensed treatment for these symptoms. ,But a ... California reveals that the patch form of hormone replacement ...
Cached Medicine News:Health News:Vitamin C maintains healthy lungs 2
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: